Clinical Trial Update: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on GPC2 CAR T cells for relapsed/refractory neuroblastoma and metastatic retinoblastoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Retinoblastoma

Drugs mentioned

• GPC2 CAR T cells

Snippet

Sponsor: Stephan Grupp MD PhD | Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Status: RECRUITING